Caricamento...
Ibrutinib in Gynecological Malignancies and Breast Cancer: A Systematic Review
Ibrutinib is an orally available, small-molecule tyrosine kinase inhibitor. Its main purpose is to inhibit Bruton’s tyrosine kinase (BTK), an enzyme that is crucial in B cell development. It is FDA approved for the treatment of certain hematological malignancies. Several promising off-target drug ef...
Salvato in:
| Pubblicato in: | Int J Mol Sci |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
MDPI
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7312555/ https://ncbi.nlm.nih.gov/pubmed/32532074 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21114154 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|